Dr Palomäki on influence of MUC5B promotor variant on ILD risk in RA and non-RA. Lifetime risk ILD 14.5% for RA+MUC5B+, 5.2% for RA+MUC5B-, 3.9% RA-MUC5B+ 1.3% RA-MUC5B- @RheumNow #EULAR2021 Abstr#OP0007 https://t.co/BnexQE1Pw9